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Abstract
Background: Several studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial
dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and
soluble endoglin (sEng), as well as to decreased PlGF. Recently, soluble VEGF type 2 receptor (sVEGFR-2) has emerged as a
crucial regulator of lymphangiogenesis. To date, however, there is a paucity of information on the changes of VEGFR-2 that
occur during the clinical onset of PE. Therefore, the aim of our study was to characterize the plasma levels of VEGFR-2 in PE
patients and to perform VEGFR-2 immunolocalization in placenta.
Methodology/Principal findings: By ELISA, we observed that the VEGFR-2 plasma levels were reduced during PE compared
with normal gestational age matched pregnancies, whereas the VEGFR-1 and Eng plasma levels were increased. The
dramatic drop in the VEGFR-1 levels shortly after delivery confirmed its placental origin. In contrast, the plasma levels of Eng
and VEGFR-2 decreased only moderately during the early postpartum period. An RT-PCR analysis showed that the relative
levels of VEGFR-1, sVEGFR-1 and Eng mRNA were increased in the placentas of women with severe PE. The relative levels of
VEGFR-2 mRNA as well as expressing cells, were similar in both groups. We also made the novel finding that a recently
described alternatively spliced VEGFR-2 mRNA variant was present at lower relative levels in the preeclamptic placentas.
Conclusions/Significance: Our results indicate that the plasma levels of anti-angiogenic factors, particularly VEGFR-1 and
VEGFR-2, behave in different ways after delivery. The rapid decrease in plasma VEGFR-1 levels appears to be a consequence
of the delivery of the placenta. The persistent circulating levels of VEGFR-2 suggest a maternal endothelial origin of this
peptide. The decreased VEGFR-2 plasma levels in preeclamptic women may serve as a marker of endothelial dysfunction.
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Introduction
Preeclampsia (PE), a syndrome affecting 2–5% of pregnancies,
is a leading cause of maternal and fetal morbidity and mortality in
developed countries [1]. This pregnancy-specific syndrome is
characterized by the onset of hypertension and proteinuria later
than 20 weeks of gestation [2]. Although PE is a multifactorial
disease, recent data indicate that imbalances between pro-
angiogenic factors, such as vascular endothelial growth factor
(VEGF) and placental growth factor (PIGF), and anti-angiogenic
factors that inhibit angiogenesis, such as soluble vascular
endothelial growth factor receptor 1 (sVEGFR-1) and soluble
endoglin (sEng), are closely related to the pathogenesis of the
disease [3,4,5,6].
The VEGFRs, VEGFR-1 and VEGFR-2, are structurally
related members of the tyrosine kinase receptor family that
mediate critical signaling pathways in endothelial cells [7]. The
kinase activity of VEGFR-1 is low compared to that of VEGFR-2
[8]. Whereas VEGFR-1 is considered to be a ‘‘decoy’’ receptor,
VEGFR-2 is regarded as the major mediator of the broad
signaling cascades that regulate many endothelial cell functions,
including proliferation, migration and differentiation [9,10].
VEGF and its receptors (VEGFR-1 and VEGFR-2, as well as
their soluble forms) are expressed in the placental trophoblasts
throughout gestation [11].
Soluble VEGFR-1, also known as soluble fms-like tyrosine
kinase 1 (sFlt-1), displays anti-VEGF and anti-PlGF activities and
is therefore a robust anti-angiogenic factor. It is increased prior to
the clinical onset of the disease in women with PE. The soluble
VEGFR-1 levels correlate with the severity and the time to the
onset of the disease [12,13]. Endoglin (Eng or CD105), a cell
surface co-receptor for the b1 and b3 isoforms of transforming
growth factor (TGF), is highly expressed in endothelial cells and
trophoblasts [14]. TGF-b3, which is strongly expressed during
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trimester (10–12 weeks), inhibits trophoblast migration and
invasion. In pregnancies complicated by early-onset preeclampsia,
TGF-b3 expression remains abnormally elevated and trophoblast
differentiation is arrested at an intermediate immature phenotype
stage [15]. The TGF-b1 levels are lower and the levels of soluble
endoglin (sEng), a truncated form of Eng, are higher in pregnant
women who subsequently develop preeclampsia than in healthy
pregnant women [16]. Circulating Eng and VEGFR-1 may
synergize and contribute to the PE syndrome through distinct but
additive mechanisms.
Whereas the role of the splice variant sVEGFR-1 in PE is well
established (see [17,18] for reviews), less is known about sVEGFR-2.
Soluble VEGFR-2 was first reported in mouse and human plasma
[19] and initially described as resulting from an endothelial cell
surface proteolytic cleavage following the ligand-induced down
expression of VEGFR-2 [20,21]. Recently, alternative splicing of the
VEGFR-2 gene hasbeen reported inmice[22]. The identified splice
variantisanendogenousVEGF-Cantagonistandacrucialregulator
of lymphatic vessel growth. The implications of this splice variant for
PE have not been determined. Circulating soluble VEGFR-2 in the
plasma of patients has been reported [19,20]. Although VEGFR-2 is
expressed in the placenta [23], there is a paucity of information
about the implications for PE pathogenesis of its circulating soluble
form and of the recently described spliced variant. This study was
therefore undertaken to evaluate plasma VEGFR-2 concentrations,
the relative placental mRNA expression and the plasma levels after
delivery in normal pregnancies and those complicated by pre-
eclampsia in comparison to sVEGFR-1 and endoglin.
Results
Demographics
The clinical characteristics of the patients in the preeclamptic
(PE) and control (NP) groups are presented in Table 1. The
gestational ages at delivery and the median birth weights of the
neonates were significantly lower in the preeclamptic group than
in the control group. The majority of the preeclamptic patients
exhibited severe proteinuria (.3 g/24 h), elevated blood pressure
(BP) ($160 mm Hg systolic BP and $100 mm Hg diastolic BP)
and low platelet counts (,100,000/mm
3). Abnormal umbilical
and uterine Doppler results were found in 19 of the 30
preeclamptic patients.
Evolution of the circulating VEGFR-2, VEGFR-1 and Eng in
the maternal plasma
The maternal plasma concentrations of VEGFR-1, VEGFR-2
and Eng were evaluated in both groups (Table 2). At delivery, the
plasma concentration of VEGFR-2 in the preeclamptic group was
significantly lower than that in the healthy, gestational-age-
matched controls (4.41 (3.93–5.27) vs. 6,54 (5.51–8.18) ng/ml,
P,0.0001). In contrast, the plasma levels of both VEGFR-1 and
Eng increased in the preeclamptic patients compared with the
gestational-age-matched controls (66.01 (46.62–100.87) vs. 4.79
(2.21–6.08) ng/ml, P,0.0001 and 43.13 (31.01–51.70) vs. 21.59
(15.22–27.74) ng/ml, P=0.0003). Therefore, both groups dis-
played inverse associations between the circulating concentrations
of VEGFR-2 and those of VEGFR-1 and Eng. Western blot
further confirmed the presence of the same immunoreactive bands
for VEGFR-1 and VEGFR-2 in the maternal circulation of the
preeclamptic women and the gestational-age matched controls
(Figure 1A). During the early postpartum period (Figure 1B), the
plasma VEGFR-2 levels were stable in the preeclamptic
(P=0.2184) and control pregnancy (P=0.2743) groups, although
a rapid and significant VEGFR-1 decrease was detected in the
plasma of the preeclamptic patients (P,0.0001) and the controls
(P,0.0001). A moderate (20%) decrease in the circulating Eng was
measured 5 days after delivery in the preeclamptic patients
(P=0.0074) and the controls (P=0.0045).
Relative mRNA quantification in the placentas
The murine corneal splice variant of the VEGFR-2 gene, which
encodes a secreted form of the protein [22], retains intron 13 and
contains an in-frame termination codon. The resulting protein
lacks the transmembrane and intracellular tyrosine kinase domains
of the membrane-bound VEGFR-2. To search for a similar
soluble splicing variant in the human placenta, we devised primers
targeting human exon 13, intron 13 and exon 16 (Table 3 and
Figure 2 A). A PCR using the exon 13 and intron 13 primers
yielded a 278-bp product that spanned the location of the splicing
event, whereas a PCR using the exon 13 and exon 16 primers
yielded a 634-bp product that corresponded to the membrane-
bound VEGFR-2.
Using those specific primers, we found that the sVEGFR-2
mRNA splice variant was less abundant in the placentas of the
preeclamptic women than in those of the controls, although the
Table 1. Clinical characteristics.
NP PE
Inclusion Delivery Inclusion Delivery
N 1 51 5 1 23 0
Maternal age (mean) 29.564.3 28.264.6 29653 0 65
Parity 2612 611 61* 161*
Primiparity 4 (27%) 6 (39%) 7 (63%) 21 (70%)
Gestational age (weeks) 30643 8 622 9 643 2 63**
BMI (kg/m
2) 21.664.4 22.765.4 23.563.7 24.464.2
Neonatal Weight (g) NA 30576468 NA 14666508**
Proteinuria.3 gr/24 h 0 0 7 (59%) 18 (60%)**
NP: normal pregnancies; PE: severe preeclampsia; NA: not applicable; BMI: body mass index.
*P,0.05 and.
**P,0.001 compared to NP group.
doi:10.1371/journal.pone.0033475.t001
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between the two groups (Figure 2 B).
The relative levels mRNA of VEGFR-1, sVEGFR-1 and
endoglin were higher in the pregnancies complicated by
preeclampsia (Figure 3).
Immunolocalization of VEGFR-1 and VEGFR-2
The cells that produce VEGFR-1 and VEGFR-2 in the
placenta were identified with immunohistochemistry. VEGFR-1
was primarily detected in the cytotrophoblasts, syncytiotropho-
blasts, endothelial cells and some stromal cells of the placentas
from normal pregnancies. A similar but more intense staining
pattern was observed in the same cell types of the placentas from
the preeclamptic women (Figure 4 A and B). VEGFR-2 was
mainly localized in the vascular endothelial cells of both the
normal and preeclamptic placental villi as revealed by serial
section staining with the CD31, blood vessel specific marker
(Figure 4 C–F and Figure S1).
Discussion
Consistent with previous reports [3,5,6,24], the circulating
plasma concentrations of VEGFR-1 and Eng were higher in the
PE than in the control group in this study (Figure 1, P,0.0001 and
P=0.0004, respectively). The soluble VEGFR-2 was identified as
a 160-kDa immunoreactive band by western blot (Figure 1A), as
also reported by Ebos et al. [19] and Albuquerque et al. [22]. The
results of the ELISA analysis indicated that this soluble VEGFR-2
isoform was present at reduced levels in the circulation of the
preeclamptic women. Other recent research has documented that
VEGFR-2 plasma levels decreased during early preeclampsia or in
pregnancies with intrauterine growth retardation [25,26,27].
Chaiworapongsa et al. also documented that the mean plasma
concentrations of VEGFR-2 are identical in nonpregnant women
(n=40) and in those experiencing normal pregnancies (n=135)
[26]. Similarly, we did not find any differences in the VEGFR-2
concentrations between 10 nonpregnant women and 15 women
with normal pregnancies (data not shown). Collectively, these data
indicate that preeclampsia is associated with decreased plasma
concentrations of VEGFR-2, whereas normal pregnancy is not.
Our study is the first to find that significantly reduced plasma
concentrations of VEGFR-2 in PE patients are associated with
decreased placental expression of the sVEGFR-2 mRNA splice
variant (Figure 2 B).
The persistently lower plasma VEGFR-2 levels observed in
postpartum PE women (Figure 1) suggest that both decreased
placental expression of the VEGFR2 spliced variant and maternal
endothelial dysfunction affect the plasma VEGFR2 levels.
Although the membrane-bound isoform of VEGFR-2 is primarily
expressed in activated maternal endothelial cells, a subset of the
circulating maternal hematopoietic cells, the CD34+ endothelial
progenitor cells, also express VEGFR-2 [28]. Therefore, maternal
endothelial dysfunction and CD34+ alterations associated with PE
Figure 1. Maternal plasma analysis. A: Western blot analysis of
VEGFR-1 and VEGFR-2 from gestational age-matched normal pregnant
women (NP, 1–5) and preeclamptic women (PE, 6–10). B: Maternal
plasma concentration of VEGFR1, VEGFR2 and Eng (mean6SE, pg/ml) at
inclusion (Incl), delivery (day 0, D 0) and during post partum (day 1 to
day 5, D 1 to D 5). PE: severe preeclampsia (plain line), NP: normal
pregnancies (dashed line).
doi:10.1371/journal.pone.0033475.g001
Table 2. Maternal plasma concentration of VEGFR-1, VEGFR-2
and Eng in normal gestational age matched to PE delivery and
preeclamptic pregnancies (median and quartiles (25
th–75
th
centile), ng/ml).
NP PE P value
VEGFR-1 4.79 (2.21–6.08) 66.01 (46.62–100.87) P,0.0001
VEGFR-2 6.54 (5.51–8.18) 4.41 (3.93–5.27) P,0.0001
Eng 21.59 (15.22–27.74) 43.13 (31.01–51.70) P=0.0003
doi:10.1371/journal.pone.0033475.t002
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associated with this condition.
After placental delivery, the plasma VEGFR-1 levels in the
preeclamptic women rapidly returned to the levels observed in
normotensive women, as would be expected for a trophoblast-
derived peptide. In contrast, the circulating plasma levels of
VEGFR-2 in the PE patients remained stable and lower than in
the normotensive women during the first 5 days after delivery, and
the Eng plasma levels remained stable and higher. The stability of
the circulating plasma levels of Eng and VEGFR-2 suggests that
these two peptides arise from both maternal sources and
trophoblasts.
Whereas VEGFR-2 is expressed on cytotrophoblast stem cells
and on cells in the proximal columns of the chorionic villi during
the first and second trimesters of pregnancy [29], at delivery
VEGFR-2 was localized almost exclusively to the placental
endothelial cells, in contrast to VEGFR-1 that is expressed mainly
by trophoblasts [11,23].
The affinity of VEGF for VEGFR-2 is at least 10-fold lower
than its affinity for VEGFR-1. Because the plasma VEGFR-2
levels are decreased by a maximum of 20%, this decrease is
probably insufficient to compensate for the VEGF inhibition
elicited by the approximately 10-fold increase in plasma VEGFR-
1.
We have previously reported that the relative expression of
VEGFR-2 mRNA in preeclamptic placental villi was similar to
that in normal placentas [5]. In that study, the total VEGFR-2
mRNA was measured using RT-PCR without discriminating
between the membrane-bound and soluble forms. Using specific
primers to quantify the mRNA levels of the full-length VEGFR-2
and its splice variant in the present study, we found that the
relative mRNA levels of the sVEGFR-2 splice variant are lower in
the placentas of the preeclamptic women than in those of the
controls, although the relative levels of membrane-bound
VEGFR-2 mRNA are similar.
During the postpartum period, the circulating plasma levels of
VEGFR-2 remained lower in the PE patients than in the women
with normal pregnancies. Because VEGFR-2 is the major
mediator of the effects of VEGF, we hypothesize that the
persistently lower plasma concentrations of VEGFR-2 in pre-
eclamptic women result from a decrease in the availability of free
VEGF to stimulate VEGFR-2 synthesis and trafficking at the
endothelial cell surfaces, as shown in other models [30]. The low
circulating plasma levels of VEGFR-2 observed in the preeclamp-
tic women may also reflect a low regenerative capacity in
endothelial cells. Indeed, preeclampsia is associated with an
endothelial dysfunction [31,32] that is characterized by increased
endothelial cell-mediated vasoconstriction, increased vascular
permeability and increased endothelium-mediated platelet aggre-
gation. These effects may lead to maternal hypertension and
proteinuria. Some researchers have found that in women with a
history of preeclampsia, impaired endothelial function may be an
indicator of cardiovascular risk [32]. Such women exhibit
impaired endothelial function for up to 1 year postpartum [33].
The concept of maternal endothelial recovery is further supported
by the 5-fold increase in circulating endothelial cells in
preeclampsia patients compared with the healthy controls. The
number of these cells declines rapidly after delivery, in parallel
with the clinical recovery of the patient [34]. The functional
manifestations of glomerular endothelial cell injury also largely
resolve within the first postpartum month [35]. The normalization
of endothelial vasoactive substances that precedes clinical recovery
in preeclamptic women after delivery further strengthens the
concept of postpartum endothelial recovery [36]. Altogether, our
data indicate that the plasma levels of anti-angiogenic factors
particularly VEGFR-2, VEGFR-1 and sEng behave in different
ways in the early postpartum period in preeclamptic women. The
persistently low level of circulating VEGFR-2 is associated with
the continued high concentration of soluble Eng and the rapid
drop in circulating placenta-derived VEGFR-1. The decreased
VEGFR-2 plasma levels in preeclamptic women may serve as a
marker of endothelial dysfunction.
Materials and Methods
Sample collection
Samples were collected from pregnant women recruited from
the department of Obstetrics and Gynecology at La Citadelle
Hospital, Lie `ge, Belgium, and from the Maternite ´ Jeanne de
Flandre, CHRU, Lille, France. The local ethics committees
approved this study, and written informed consent was obtained
from all the patients.
Thirty subjects had severe preeclampsia (PE), which was defined
using the hypertension, edema and proteinuria criteria. Hyper-
tension was defined as systolic and diastolic blood pressures above
160 mmHg and 100 mmHg, respectively, in at least two
consecutive measurements spaced 4 hours apart. Severe protein-
uria was defined as more than 300 mg per 24 hours or a urine
sample with proteinuria of at least 3+. Thirty patients with non-
complicated pregnancies (NP) constituted the control group for the
plasma measurements. None of the patients had chronic
hypertension, renal diseases or endocrine diseases. Among the
control group, blood was collected from 15 gestational-age-
matched to PE delivery. All the blood samples (PE and NP) were
collected in tubes containing EDTA. The samples were centri-
fuged at 3000 rpm during 20 minutes at 4uC. The plasma aliquots
were stored at 280uC until analysis.
Table 3. Sequence of primers and TaqMan probes used for
RT-PCR studies.
Gene (Accession N6) Sequence
VEGFR1-FP 59-TCCCTTATGATGCCAGCAAGT-39
VEGFR1-RP 59-CCAAAAGCCCCTCTTCCAA-39
VEGFR1 Probe 59-CCGGGAGAGACTTAAACTGGGCAAATCA-39
AF063657
sVEGFR1-FP 59-ACAATCAGAGGTGAGCACTGCAA-39
sVEGFR1-RP 59-TCCGAGCCTGAAAGTTAGCAA-39
sVEGFR1 Probe 59-TCCAAATTTAAAAGCACAAGGAATGATTGTACCAC-
39
U01134
VEGFR2-FP 59-CTTGGCCCACAGCCTCTGCC-39
VEGFR2-RP 59-GTTCCCCTCCATTGGCCCGC-39
NM_002253
sVEGFR2-FP 59-CTTGGCCCACAGCCTCTGCC-39
sVEGFR2-RP 59-GGCATTCCAACTGCCTCTGCAC-39
NM_002253+NT_022853
ENG-FP 59-TTTGTCTTGCGCAGTGCTTACT-39
ENG-RP 59-TTTTCCGCTGTGGTGATGA -39
ENG Probe 59-TGAGGCGGTGGTCAATATCCTGTCGA-39
NM_000118
doi:10.1371/journal.pone.0033475.t003
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cesarean section (NP=15 and PE=18). The tissue samples were
frozen in liquid nitrogen within 30 minutes after the birth and
stored at 280uC until further analysis. Maternal plasma was
additionally collected between postpartum days 1 and 5.
Immunoassays
The plasma levels of VEGFR-1, VEGFR-2 and Eng were
measured with an enzyme-linked immunoassay (ELISA) technique
using DuoSetH human immunoassays (R&D Systems Europe Ltd.,
Abington, UK). The lower limits of detection of the assays were
15 pg/ml for VEGFR-1 and 5 pg/ml for VEGFR-2 and ENG.
All the samples were measured in duplicate. The samples with
duplicate coefficients of variation exceeding 15% were reanalyzed.
For western blotting the maternal plasma (diluted 1:20, 20 ml/
lane) was separated by 8.5% SDS-PAGE and transferred onto
polyvinylidene difluoride (PVDF, Immobilon
TM-P, Millipore,
Billerica, MA, USA) membranes. After activation in 100%
methanol, the blots were incubated for 1 h at room temperature
in TBS-T/casein (TBS-T (Tris-HCl 20 mM, NaCl 140 mM,
TweenH 20 0.2%, pH 7.6) containing 1% casein) (Sigma-Aldrich,
St Louis, MO, USA). After being washed, the membranes were
incubated overnight at 4uC with either the VEGFR-2 antibody
(AF357, diluted 1:500, R&D Systems) or the VEGFR-1 antibody
(AF321, diluted 1:500, R&D Systems) in TBS-T containing 1%
BSA. After being washed, the membranes were incubated for 1 h
at room temperature with the appropriate secondary HRP-linked
antibody diluted in TBS-T/BSA (P0449, Dako Cytomation) and
were washed again. The immunocomplexes were visualized via a
chemiluminescence reaction (PierceH ECL Western Blotting
Substrate, Thermo Scientific, Rockford, IL, USA) on a lumines-
cent image analyzer (LAS-4000, Fujifilm, Wavre, Belgium).
RT-PCR analysis
The placenta tissue biopsies from the 18 PE and 15 NP women
were immediately snap frozen and stored in liquid nitrogen until
the analysis. The frozen tissues were processed as previously
described [5]. For real-time quantitative RT-PCR analyses gene-
specific primers and TaqMan fluorescent hybridization probes
(Eurogentec, Lie `ge, Belgium) for the VEGFR-1, sVEGFR-1 and
ENG mRNAs were used (Table 3). Primers sequences were
deposit in a public database (RTPrimerDB: http://www.rtpri
merdb.org/). The PCR was performed using the ABI PRISM
7700 Sequence Detection System instrument and software (PE
Applied Biosystems, Inc., Foster City, CA). The expression level of
each gene of interest was computed relative to that of 18S rRNA
Figure 2. Placental VEGFR-2 and sVEGFR-2 relative mRNA levels. A: Schematic representation of pre-mRNA exon-intron structure of VEGFR-2
(central shadowed box not at scale) with primers used to discriminate membrane bound VEGFR-2 mRNA (upper box, exon 13-exon 16; 634 bp) and
soluble VEGFR-2 mRNA (lower box, exon 13-intron 13; 278 bp). B: Relative mRNA levels are expressed as arbitrary units (A.U.). NP: normal
pregnancies, PE: severe preeclampsia. **P,0.001 compared to NP group; ns: non-significant compared to NP group.
doi:10.1371/journal.pone.0033475.g002
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normalize the variations in the RNA quality and in the amount
of input cDNA, as previously described [5]. All the primers, except
those specific for VEGFR2, were designed to produce fragments
that spanned the exon-intron boundaries, thus preventing the
amplification of genomic DNA. The sVEGFR-2 reverse primer
recognized an intron 13 motif that is specific to the truncated
transcript variant of the secreted form of VEGFR-2 [22]. The RT-
PCR products specific for the VEGFR-2 and sVEGFR-2 mRNAs
were measured in 10-ng aliquots of cDNA using Taq polymerase
(Takara, Shiga, Japan) and 5 pmol of each primer (Table 3). The
PCR products were resolved on 10% polyacrylamide gels (Bio-
Rad) and analyzed with a luminescent image analyzer (LAS-4000,
Fujifilm) after GelStar staining (Lonza Rockland, Inc., Rockland,
ME). The specific mRNA levels were expressed as the ratios of the
specific transcripts to the 18S rRNA.
Immunohistochemistry
The placentas were fixed in 4% formalin for 4 to 12 hours,
embedded in paraffin and cut into 4-mm sections. The sections
were mounted on SuperFrost Plus glass slides (Menzel-Gla ¨ser,
LaboNord), dewaxed in xylene, rehydrated and subsequently
autoclaved for 11 min at 126uC and 1.4 bar in Target Retrieval
Buffer (S2031, DakoCytomation, Glostrup, Denmark). The
endogenous peroxidases were blocked by treatment with 3%
H2O2/H2O for 20 min, and non-specific binding was prevented
by incubation in Universal Blocking Reagent (BioGenex, San
Ramon, CA, USA) for 3 min. The sections were incubated
overnight at 4uC with the primary antibody (VEGFR-1, R&D
Systems, AF321, diluted 1:300; VEGFR-2, R&D Systems, AF357,
diluted 1:100, CD-31, Dako, M0823, diluted 1:40). The sections
were washed in TBS (Tris-buffered saline) with 0.1% Tween and
then incubated for 30 min with a secondary antibody (biotinylated
rabbit anti-goat (Dako E0466, diluted 1:400) or biotinylated goat
anti-mouse (Dako K0433, diluted 1:400)), followed by incubation
with peroxidase-labeled streptavidin for 30 min (Dako P0397,
diluted 1:500). The staining was detected with DAB chromogen
after 5 min or with permanent red substrate (Dako K0640) for
CD31. The nuclei were counterstained by incubation with
hematoxylin for 2 min. The sections were mounted, examined
and photographed. The control samples were processed by
omitting the primary antibody or by incubating the sections with
nonspecific IgG at the same concentration as the primary
antibody.
Statistical analyses
The patient groups were compared using the Kruskal-Wallis
test, and significant differences were further analyzed via
pairwise comparisons using the Mann-Whitney test. The
results are presented as medians6quartiles (25
th–75
th quartiles)
or means6SE. P values,0.05 were considered statistically
significant.
Figure 3. Placental VEGFR-1, sVEGFR-1 and Eng relative mRNA levels. Relative mRNA levels are expressed as arbitrary units (A.U.). NP:
normal pregnancies, PE: severe preeclampsia. **P,0.001 compared to NP group; ns: non-significant compared to NP group.
doi:10.1371/journal.pone.0033475.g003
Antiangiogenic Factors in Preeclampsia
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33475Supporting Information
Figure S1 Representative immunolocalization of, aSMA
(A), VEGFR-2 (B) and CD31 (C) in serial sections of
normal placental villi. Double immunofluorescences of aSMA
(green) and VEGFR-2 (red) (D–F) or CD31 (green) and VEGFR-2
(red) (G–I). Nuclei are counterstained with DAPI (blue).
(DOCX)
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